Toxicologic Pathology Forum*: Opinion on Assessing and Communicating Adversity for Implantable Medical Devices
Toxicologic Pathology · 2025
DOI: 10.1177/01926233241300313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicologic Pathology, 2025. Verfasst von L M Wancket und 3 weiteren Autor:innen. Beteiligte Einrichtung: Charles River Laboratories, Mattawan, Michigan, USA. Hauptthemen laut MEDLINE: Prostheses and Implants, Equipment and Supplies, Toxicology. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Medical devices are a product class encompassing many materials and intended uses. While adversity determination is a key part of nonclinical safety assessments, relatively little has been published about the unique challenges encountered when determining adversity for implantable medical devices. The current paper uses the Society of Toxicologic Pathology (STP)’s “Scientific and Regulatory Policy Committee Recommended (‘Best’) Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies,” which were crafted for conventional bio/pharmaceutical products (small and large molecules, cell and gene therapies, etc), as a framework for making adversity decisions for medical devices. Some best principles are directly translatable to medical devices: (1) adversity indicates harm to the animal; (2) effects should be assessed on their merits without speculation regarding future or unmeasured implications; (3) adversity decisions apply only to the test species under the specific conditions of the nonclinical study; and (4) adversity decisions and supporting evidence should be clearly stated in reports. However, unique considerations also apply for evaluating implanted medical devices, including testing of multiple articles in the same animal and the unavoidable tissue trauma during device implantation. This opinion piece offers suggestions for applying previously published STP best practice recommendations for assigning adversity to implantable medical devices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Charles River Laboratories, Mattawan, Michigan, USA.
- GEMpath, Inc., Longmont, Colorado, USA.
- Experimental Pathology Laboratories, Inc., Sterling, Virginia, USA.
- Retired Consultant, Bainbridge Island, Washington, USA.
ORCID-Profile: L M Wancket, B Bolon, K A Funk, J C L Schuh
Zitieren
APA
Wancket, L. M., Bolon, B., Funk, K. A., & Schuh, J. C. L. (2025). Toxicologic Pathology Forum*: Opinion on Assessing and Communicating Adversity for Implantable Medical Devices. Toxicologic Pathology. https://doi.org/10.1177/01926233241300313
Vancouver
Wancket LM, Bolon B, Funk KA, Schuh JCL. Toxicologic Pathology Forum*: Opinion on Assessing and Communicating Adversity for Implantable Medical Devices. Toxicologic Pathology. 2025. doi:10.1177/01926233241300313
BibTeX
@article{Wancket2025,
author = {Wancket, L M and Bolon, B and Funk, K A and Schuh, J C L},
title = {Toxicologic Pathology Forum*: Opinion on Assessing and Communicating Adversity for Implantable Medical Devices},
journal = {Toxicologic Pathology},
year = {2025},
doi = {10.1177/01926233241300313}
}
EUVIMED